Skip to main content

Table 3 Comparison of pretreatment clinical characteristics of older patients with acute myeloid leukemia assigned to the genetic groups

From: A precision medicine classification for treatment of acute myeloid leukemia in older patients

Characteristic

CBF

n = 74

NPM1m/ FLT3-ITD‒

n = 107

KMT2A

n = 13

IDH2m

n = 59

IDH1m

n = 35

TP53m

n = 50

Complex

karyotype/TP53wt

n = 28

FLT3m

n = 99

TET2m or WT1m

n = 42

Marker-negative

n = 56

Age, years

          

 Median

 Range

66

(60, 78)

68

(60, 84)

69

(60, 77)

71

(60, 86)

71

(60, 85)

70

(60, 84)

69

(61, 78)

70

(60, 89)

71

(62, 85)

69

(60, 86)

Sex, n (%)

          

 Male

37 (50)

54 (50)

7 (54)

36 (61)

19 (54)

29 (58)

20 (71)

55 (56)

26 (62)

35 (63)

 Female

37 (50)

53 (50)

6 (46)

23 (39)

16 (46)

21 (42)

8 (29)

44 (44)

16 (38)

21 (38)

Race, n (%)

          

 White

61 (86)

98 (92)

11 (85)

55 (95)

31 (91)

42 (86)

23 (85)

90 (94)

38 (90)

51 (93)

 Non-white

10 (14)

8 (8)

2 (15)

3 (5)

3 (9)

7 (14)

4 (15)

6 (6)

4 (10)

4 (7)

Hemoglobin, g/dL

          

 Median

 Range

8.8

(4.8, 12.4)

9.4

(5.3, 14.1)

8.5

(5.7, 11.5)

9.3

(5.2, 13.9)

9.4

(6.5, 13.8)

9.2

(6.8, 11.5)

9.4

(6.0, 14.7)

9.5

(4.3, 15.0)

9.1

(3.0, 11.9)

9.1

(6.2, 12.7)

Platelet count, × 109/L

          

 Median

 Range

42

(7, 237)

75

(6, 507)

45

(8, 242)

68

(5, 673)

103

(5, 850)

44

(9, 224)

48

(4, 426)

53

(9, 387)

41

(7, 510)

56

(7, 281)

WBC count, × 109/L

          

 Median

 Range

15.2

(1.4, 252.0)

29.3

(0.6, 308.5)

41.6

(2.2, 172.9)

13.4

(0.6, 434.1)

11.8

(0.7, 248.0)

7.8

(0.4, 118.0)

18.4

(0.6, 116.1)

52.4

(0.8, 450.0)

23.5

(2.2, 229.5)

14.5

(1.1, 110.0)

% Blood Blasts

          

 Median

 Range

40

(0, 96)

40

(0, 97)

71

(1, 99)

46

(0, 97)

55

(0, 99)

27

(0, 88)

34

(0, 94)

69

(0, 97)

57

(0, 99)

33

(0, 86)

% Bone marrow blasts

          

 Median

 Range

56

(10, 90)

70

(0, 95)

85

(46, 97)

70

(21, 99)

81

(34, 93)

47

(17, 90)

50

(16, 88)

80

(6, 99)

62

(26, 96)

60

(17, 94)

Extramedullary involvement, n (%)

14 (23)

28 (28)

2 (15)

15 (28)

4 (12)

7 (16)

6 (24)

28 (30)

9 (22)

7 (13)

ELN 2017, n (%)

          

 Favorable

74 (100)

107 (100)

0 (0)

6 (11)

2 (6)

1 (2)

1 (4)

22 (23)

4 (11)

4 (8)

 Intermediate

0 (0)

0 (0)

8 (62)

27 (47)

16 (48)

0 (0)

0 (0)

40 (43)

16 (42)

15 (30)

 Adverse

0 (0)

0 (0)

5 (38)

24 (42)

15 (45)

49 (98)

27 (96)

32 (34)

18 (47)

30 (60)

ECOG performance status, n (%)

          

 Grade 0

17 (30)

25 (26)

2 (17)

13 (23)

12 (40)

9 (20)

6 (26)

18 (20)

13 (33)

18 (38)

 Grade 1

25 (44)

44 (45)

5 (42)

27 (48)

11 (37)

21 (47)

14 (61)

40 (45)

17 (43)

21 (44)

 Grade 2

11 (19)

26 (27)

4 (33)

11 (20)

6 (20)

9 (20)

3 (13)

25 (28)

7 (18)

8 (17)

 Grade 3

4 (7)

3 (3)

1 (8)

2 (4)

1 (3)

5 (11)

0 (0)

6 (7)

3 (8)

0 (0)

 Grade 4

0 (0)

0 (0)

0 (0)

3 (5)

0 (0)

1 (2)

0 (0)

0 (0)

0 (0)

1 (2)

  1. CBF, core-binding factor; dL, deciliter; ELN, European LeukemiaNet; g, gram; L, liter; m, mutated; n, number; WBC, white blood cell; wt, wild-type
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us